Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™

Core Viewpoint - Apyx Medical Corporation has received FDA 510(k) clearance for the AYON Body Contouring System, marking a significant advancement in aesthetic surgical technology and is set to launch commercially in the second half of 2025 [1][6]. Group 1: Product Overview - The AYON Body Contouring System is an all-in-one platform designed for body contouring, integrating fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities [3][4]. - It features LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, aiming to improve surgical precision and patient outcomes [3][6]. - The system is expected to revolutionize body contouring procedures and is backed by Apyx Medical's expertise and evidence-based design [3][6]. Group 2: Market Context - The aesthetics market is projected to see a rapid increase in body contouring procedures, particularly as over 15 million patients using GLP-1 drugs experience significant weight loss and seek solutions for loose skin [6]. - The initial FDA clearance for AYON covers various aesthetic treatments, including ultrasound-assisted liposuction and electrocoagulation for tissue removal, with plans for further indications like power liposuction [4][5]. Group 3: Company Background - Apyx Medical Corporation specializes in advanced energy technology, particularly its Helium Plasma Platform Technology products marketed as Renuvion and the AYON Body Contouring System [7]. - The effectiveness of Renuvion and J-Plasma technologies is supported by over 90 clinical documents, showcasing the company's commitment to innovation in surgical solutions [7].